➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 6,566,064

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,566,064
Title: Method for anticipating sensitivity to medicine for osteoporosis
Abstract:A method for anticipating sensitivity to a medicine for osteoporosis is provided which is characterized by analyzing respective genetic polymorphisms of a vitamin D receptor gene, an estrogen receptor gene, and an apolipoprotein E gene from a genome DNA contained in a sample obtained from a human, and anticipating, based on the analyzed combination of the genetic polymorphisms, that the sample is derived from an individual who shows a specific priority to sensitivities to a plurality of remedies for osteoporosis. A reagent for simultaneously detecting genetic polymorphisms is also provided which contains amplification primers and/or detection probes specific to respective genes of the vitamin D receptor gene, apolipoprotein E gene, and estrogen receptor gene. Further, a method for simultaneously detecting these genes, and a method for selecting remedies for bone disease based on the genetic polymorphisms are provided. According to the method of the present invention, a diagnosis as to which remedy, or medicine, for osteoporosis a subject patient has higher sensitivity can be made before the administration of the medicine so that selection of an appropriate medicine is possible and the QOL (quality of life) of the patient can be improved.
Inventor(s): Shiraki; Masataka (Misato-mura, JP), Ouchi; Yasuyoshi (Tokyo-to, JP), Hosoi; Takayuki (Tokyo-to, JP), Kusaba; Nobutaka (Osaka, JP), Baba; Toshiaki (Osaka, JP), Yoshida; Hiroshi (Osaka, JP)
Assignee: Nipro Corporation (Osaka, JP)
Application Number:09/572,891
Patent Claims:see list of patent claims

Details for Patent 6,566,064

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Nipro Corporation (Osaka, JP) 2019-05-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Nipro Corporation (Osaka, JP) 2019-05-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Nipro Corporation (Osaka, JP) 2019-05-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.